NYSE · CIK 0001174940
OGEN ORAGENICS INC
Insider trading from SEC Form 4. Last filing Jul 7, 2026. Close $0.45 on Oct 12, 2026, 0% from the 52-week low and -68% from the high.
In brief
ORAGENICS INC (OGEN) has 15 SEC Form 4 filings on file from 9 insiders, the latest filed on Jul 7, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
7 open-market trades have been scored at OGEN. The newest: Fred Telling (director) sold $198 of stock on Dec 12, 2025, filed Jan 22, 2026, scored 20 (weak). The largest of the 7 shown: Odyssey Health, Inc. (10% owner) sold $44k on Jun 13, 2025, scored 38 (weak). 2 insiders sold within 14 days of each other around Dec 6, 2024.
5 Form 144 notices of planned sales are on file, the latest filed Dec 12, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ORAGENICS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Fred Telling director sell | $198 210 shares | -18% | +8% from low-93% from high | |
| 15Weak | Fred Telling director sell | $198 210 shares | -1% | +8% from low-93% from high | |
| 37Weak | Odyssey Health, Inc. owner sell | $30k 7,044 shares | -100% | +24% from low-73% from high | |
| 38Weak | Odyssey Health, Inc. owner sell | $44k 10,000 shares | -59% | +24% from low-73% from high | |
| 23Weak | Alan W Dunton director sell | $24 66 shares | -0% | - | |
| 23Weak | Fred Telling director sell | $1,295 3,597 shares | -9% | - | |
| 15Weak | Fred Telling director sell | $12k 3,500 shares | -8% | +37% from low-70% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 12, 2025 | Frederick W. Telling Director | 210 0.01% of outstanding | $192 | Dec 12, 2025 | none |
| Jun 13, 2025 | Odyssey Health, Inc. Stockholder | 17,044 2.38% of outstanding | $80k | Jun 10, 2025 | none |
| Dec 6, 2024 | DUNTON ALAN W Director | 66 0.00% of outstanding | $22 | Dec 6, 2024 | none |
| Dec 6, 2024 | Frederick Telling Director | 3,597 0.03% of outstanding | $1,294 | Dec 6, 2024 | none |
| Nov 30, 2023 | Frederick W. Telling Director | 3,500 0.14% of outstanding | $13k | Nov 30, 2023 | none |
Transactions
Every row filed, 21 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | John Spencer Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +55,900 | $0.00 | $0 | 55,900 | Jul 7, 2026 |
| Dec 12, 2025 | Fred Telling director | SOpen-market sale Common Stock | -210 | $0.94 | $198 | 948 | Jan 22, 2026 |
| Dec 11, 2025 | Fred Telling director | AGrant or award Non-Employee Director Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Jan 22, 2026 |
| Dec 12, 2025 | Fred Telling director | SOpen-market sale Common Stock | -210 | $0.94 | $198 | 34,538 | Dec 15, 2025 |
| Dec 11, 2025 | Alan W Dunton director | AGrant or award Non-Employee Director Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 15, 2025 |
| Dec 11, 2025 | John P Gandolfo director | AGrant or award Non-Employee Director Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 15, 2025 |
| Dec 11, 2025 | Natasha Giordano director | AGrant or award Non-Employee Director Option (Right to Buy)derivative | +38,320 | $0.00 | $0 | 38,320 | Dec 15, 2025 |
| Dec 11, 2025 | Janet Huffman CEO and CFO | AGrant or award Employee Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Dec 15, 2025 |
| Dec 11, 2025 | Robert C Koski director | AGrant or award Non-Employee Director Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 15, 2025 |
| Dec 11, 2025 | Charles L Pope director | AGrant or award Non-Employee Director Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 15, 2025 |
| Dec 11, 2025 | Fred Telling director | AGrant or award Non-Employee Director Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 15, 2025 |
| Dec 11, 2025 | Natasha Giordano director | AGrant or award Non-Employee Director Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 15, 2025 |
| Jun 17, 2025 | Odyssey Health, Inc. owner | SOpen-market sale Common Stock - OGEN | -2,000 | $4.46 | $8,920 | 5,044 | Jun 18, 2025 |
| Jun 18, 2025 | Odyssey Health, Inc. owner | SOpen-market sale Common Stock - OGEN | -5,044 | $4.26 | $21k | 0 | Jun 18, 2025 |
| Jun 13, 2025 | Odyssey Health, Inc. owner | SOpen-market sale Common Stock - OGEN | -5,000 | $4.27 | $21k | 12,044 | Jun 16, 2025 |
| Jun 16, 2025 | Odyssey Health, Inc. owner | SOpen-market sale Common Stock - OGEN | -5,000 | $4.45 | $22k | 7,044 | Jun 16, 2025 |
| Dec 11, 2024 | Robert C Koski director | CConversion Common Stockindirect: See Footnote | +5,000 | - | - | 23,367 | Dec 13, 2024 |
| Dec 11, 2024 | Robert C Koski director | CConversion Series B Convertible Preferred Stockderivativeindirect: See Footnote | -1,500,000 | - | - | 0 | Dec 13, 2024 |
| Dec 6, 2024 | Alan W Dunton director | SOpen-market sale Common Stock | -66 | $0.36 | $24 | 25,623 | Dec 9, 2024 |
| Dec 6, 2024 | Fred Telling director | SOpen-market sale Common Stock | -3,597 | $0.36 | $1,295 | 34,748 | Dec 9, 2024 |
| Nov 30, 2023 | Fred Telling director | SOpen-market sale Common Stock | -3,500 | $3.57 | $12k | 38,345 | Dec 1, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Alan W Duntondirector
- John P Gandolfodirector
- Natasha Giordanodirector
- Janet HuffmanCEO and CFO
- Robert C Koskidirector
- Odyssey Health, Inc.owner
- Charles L Popedirector
- John SpencerChief Financial Officer
- Fred Tellingdirector
Questions about OGEN
Answered from the filings on this page, as of the latest one.
Are insiders buying OGEN?
No. In the last 90 days no insider at ORAGENICS INC bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade OGEN on the open market?
Fred Telling (director) sold $198 of OGEN on Dec 12, 2025 and filed the Form 4 on Jan 22, 2026. InsiderTell scored 20 (weak).
How many insiders file Form 4 at ORAGENICS INC?
9 people have filed a Form 4 at ORAGENICS INC, among them Alan W Dunton (director), John P Gandolfo (director), Natasha Giordano (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.